JP2008533127A - 慢性便秘を治療するためのメトホルミン方法と製剤 - Google Patents

慢性便秘を治療するためのメトホルミン方法と製剤 Download PDF

Info

Publication number
JP2008533127A
JP2008533127A JP2008501452A JP2008501452A JP2008533127A JP 2008533127 A JP2008533127 A JP 2008533127A JP 2008501452 A JP2008501452 A JP 2008501452A JP 2008501452 A JP2008501452 A JP 2008501452A JP 2008533127 A JP2008533127 A JP 2008533127A
Authority
JP
Japan
Prior art keywords
metformin
formulation
release
dosage
dosage formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008501452A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008533127A5 (enExample
Inventor
デヴェイン，ジョン
Original Assignee
エイジーアイ・セラピューティクス・リサーチ・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エイジーアイ・セラピューティクス・リサーチ・リミテッド filed Critical エイジーアイ・セラピューティクス・リサーチ・リミテッド
Publication of JP2008533127A publication Critical patent/JP2008533127A/ja
Publication of JP2008533127A5 publication Critical patent/JP2008533127A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2008501452A 2005-03-18 2006-03-16 慢性便秘を治療するためのメトホルミン方法と製剤 Pending JP2008533127A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66292005P 2005-03-18 2005-03-18
PCT/IB2006/002233 WO2007007189A2 (en) 2005-03-18 2006-03-16 Metformin methods and formulations for treating chronic constipation

Publications (2)

Publication Number Publication Date
JP2008533127A true JP2008533127A (ja) 2008-08-21
JP2008533127A5 JP2008533127A5 (enExample) 2009-05-07

Family

ID=37637555

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008501452A Pending JP2008533127A (ja) 2005-03-18 2006-03-16 慢性便秘を治療するためのメトホルミン方法と製剤

Country Status (10)

Country Link
US (1) US20060222709A1 (enExample)
EP (1) EP1865939A2 (enExample)
JP (1) JP2008533127A (enExample)
AU (1) AU2006268003A1 (enExample)
CA (1) CA2599531A1 (enExample)
IL (1) IL185652A0 (enExample)
MX (1) MX2007011174A (enExample)
NO (1) NO20075344L (enExample)
WO (1) WO2007007189A2 (enExample)
ZA (1) ZA200707325B (enExample)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014501787A (ja) * 2011-01-07 2014-01-23 エルセリクス セラピューティクス インコーポレイテッド 化学感覚受容体リガンドに基づく治療法
JP2015503591A (ja) * 2012-01-06 2015-02-02 エルセリクス セラピューティクス インコーポレイテッド 代謝障害を治療するための組成物および方法
JP2015503582A (ja) * 2012-01-06 2015-02-02 エルセリクス セラピューティクス インコーポレイテッド ビグアナイド組成物および代謝障害を治療する方法
JP2015522080A (ja) * 2012-07-11 2015-08-03 エルセリクス セラピューティクス インコーポレイテッド スタチン、ビグアナイド、およびさらなる薬剤を含む心血管代謝性リスクを減少させるための組成物
JP2015531770A (ja) * 2012-08-29 2015-11-05 サリックス ファーマシューティカルズ，インコーポレイテッド 緩下剤組成物、ならびに便秘および関連胃腸疾患および症状を処置するための方法
US10603291B2 (en) 2012-01-06 2020-03-31 Anji Pharma (Us) Llc Compositions and methods for treating metabolic disorders
JP2021506750A (ja) * 2017-12-18 2021-02-22 バイエル・アクチエンゲゼルシヤフト アカルボースおよびメトホルミンの固定用量組合せ錠剤製剤およびその製造方法
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2367554A4 (en) * 2008-11-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Bile acid reflux inhibitor for the treatment of obesity and diabetes
EP4137137A1 (en) 2010-05-26 2023-02-22 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
EP2599789A1 (en) * 2011-12-01 2013-06-05 Bergen Teknologioverføring AS Marker and method for diagnosing diarrhea syndrome
EP2941245B1 (en) * 2013-01-05 2024-06-26 Anji Pharmaceuticals Inc. Delayed-release composition comprising biguanide
CN104434846A (zh) * 2014-11-17 2015-03-25 中国药科大学 盐酸二甲双胍肠溶缓释微丸及其制备方法
EP4045520A1 (en) 2019-10-16 2022-08-24 Bayer Aktiengesellschaft Methods for the improved formation of acarbose
JP2025535564A (ja) 2022-11-07 2025-10-24 リジュベネイト バイオメッド エヌブイ メトホルミンミニ錠剤
CN121846068A (zh) * 2023-08-22 2026-04-14 雅研(天津)生物医药科技中心(有限合伙) 盐酸二甲双胍肠溶制剂

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002529504A (ja) * 1998-11-12 2002-09-10 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー インスリン感作物質および他の抗糖尿病薬の放出修飾のための医薬組成物
US20040096499A1 (en) * 2002-08-05 2004-05-20 Navin Vaya Novel dosage form
US6790459B1 (en) * 2000-11-03 2004-09-14 Andrx Labs, Llc Methods for treating diabetes via administration of controlled release metformin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047128A1 (en) * 1998-03-19 1999-09-23 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
US6676966B1 (en) * 2000-05-09 2004-01-13 Intellipharmaceutics Corp. Extended release metformin hydrochloride formulations
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002529504A (ja) * 1998-11-12 2002-09-10 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー インスリン感作物質および他の抗糖尿病薬の放出修飾のための医薬組成物
US6790459B1 (en) * 2000-11-03 2004-09-14 Andrx Labs, Llc Methods for treating diabetes via administration of controlled release metformin
US20040096499A1 (en) * 2002-08-05 2004-05-20 Navin Vaya Novel dosage form

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ABDALLAH O Y, SCIENCES TECHNIQUES ET PRATIQUES STP PHARMA, vol. V4 N1, JPN5008001815, 1988, FR, pages 15 - 20, ISSN: 0002215785 *
HOSNY, E. A. ET AL: "Enteric-coated insulin capsules: a combination with or a replacement of oral hypoglycaemic drugs.", BOLLETTINO CHIMICO FARMACEUTICO, vol. 141, no. 5, JPN6012022808, 2002, pages 379 - 384, ISSN: 0002215786 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11065215B2 (en) 2011-01-07 2021-07-20 Anji Pharma (Us) Llc Biguanide compositions and methods of treating metabolic disorders
JP2014501787A (ja) * 2011-01-07 2014-01-23 エルセリクス セラピューティクス インコーポレイテッド 化学感覚受容体リガンドに基づく治療法
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US10610500B2 (en) 2011-01-07 2020-04-07 Anji Pharma (Us) Llc Chemosensory receptor ligand-based therapies
US10668031B2 (en) 2011-01-07 2020-06-02 Anji Pharma (Us) Llc Biguanide compositions and methods of treating metabolic disorders
JP2015503591A (ja) * 2012-01-06 2015-02-02 エルセリクス セラピューティクス インコーポレイテッド 代謝障害を治療するための組成物および方法
JP2015503582A (ja) * 2012-01-06 2015-02-02 エルセリクス セラピューティクス インコーポレイテッド ビグアナイド組成物および代謝障害を治療する方法
US10603291B2 (en) 2012-01-06 2020-03-31 Anji Pharma (Us) Llc Compositions and methods for treating metabolic disorders
JP2015522080A (ja) * 2012-07-11 2015-08-03 エルセリクス セラピューティクス インコーポレイテッド スタチン、ビグアナイド、およびさらなる薬剤を含む心血管代謝性リスクを減少させるための組成物
JP2018087214A (ja) * 2012-07-11 2018-06-07 エルセリクス セラピューティクス インコーポレイテッド スタチン、ビグアナイド、およびさらなる薬剤を含む心血管代謝性リスクを減少させるための組成物
JP2015531770A (ja) * 2012-08-29 2015-11-05 サリックス ファーマシューティカルズ，インコーポレイテッド 緩下剤組成物、ならびに便秘および関連胃腸疾患および症状を処置するための方法
JP2021506750A (ja) * 2017-12-18 2021-02-22 バイエル・アクチエンゲゼルシヤフト アカルボースおよびメトホルミンの固定用量組合せ錠剤製剤およびその製造方法
JP7346404B2 (ja) 2017-12-18 2023-09-19 バイエル・アクチエンゲゼルシヤフト アカルボースおよびメトホルミンの固定用量組合せ錠剤製剤およびその製造方法

Also Published As

Publication number Publication date
US20060222709A1 (en) 2006-10-05
EP1865939A2 (en) 2007-12-19
CA2599531A1 (en) 2007-01-18
ZA200707325B (en) 2009-03-25
WO2007007189A2 (en) 2007-01-18
AU2006268003A1 (en) 2007-01-18
MX2007011174A (es) 2008-02-11
NO20075344L (no) 2007-10-18
IL185652A0 (en) 2008-01-06
WO2007007189A3 (en) 2007-04-26

Similar Documents

Publication Publication Date Title
US20060222709A1 (en) Metformin methods and formulations for treating chronic constipation
RU2207856C2 (ru) Способ лечения сердечно-сосудистых заболеваний
US20040202718A1 (en) Dosage form for treatment of diabetes mellitus
US20040052844A1 (en) Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins
US20060134206A1 (en) Oral compositions for treatment of diseases
US20070172525A1 (en) Anti-diabetic combinations
US11331274B2 (en) Milrinone controlled-release formulation
JP2009532331A (ja) 鎮静剤および睡眠剤の経口放出制御製剤
JP2004534768A (ja) ビグアニドおよび少なくとももう一つの活性成分を含む、経口投与形態を有する１日１回投与の抗糖尿病薬。
KR20120065328A (ko) １-［２-（２,４-디메틸-페닐술파닐）-페닐］피페라진의 신규한 조성물
JP2022163681A (ja) 治療方法
CN115297848B (zh) 一种非布司他片
US20060229261A1 (en) Acarbose methods and formulations for treating chronic constipation
MXPA05003177A (es) Uso de (r) verapamil para el tratamiento de aumentos anormales en movilidad gastrointestinal.
EP3796908B1 (en) Controlled release propiverine formulations
EP4601624A2 (en) Modified release tolcapone formulations
AU2002348712A1 (en) Dosage form for treatment of diabetes mellitus

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090313

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110915

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120502

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121003